Vol 25, No 1 (2019)

The purpose of the study is to study the peculiarities of organization of care for patients in the nursing Office. An analysis of case histories of 504 patients treated in the Nursing Department and 200 questionnaires of patients and their relatives about the quality of care and assistance. Considered the composition of the patients, the availability of diagnostic studies and consultation expertise, especially providing diagnostic assistance offices, nursing care, treatment outcomes, consumer opinion medical services.

Aim: Identification of predictors of unfavorable annual prognosis in patients with acute coronary syndrome with ST-segment elevation (STEMI). Material and methods: The study included 69 patients with STEMI who were hospitalized in the period from March 2014 to January 2017 in the hospital named after Zhadkevich. The follow-up period was 12±3 months after the index STEMI Longterm prognosis was established in 62 (89.8%) patients. Results: the fatal outcome was observed in 7 (11.3%) patients. Nonfatal myocardial infarction developed in 10 (16.2%), hospitalization with heart failure decompensation - in 5 (8%), nonfatal acute cerebrovascular accident - in 3 (4.8%) patients. Predictors of adverse prognosis were: age >60 years, level of brain natriuretic peptide (BNP) >29.2 pmol/l, C-reactive protein (CRP) >4.7 mg/l, left ventricular ejection fraction (LVF) <42%. The final model for predicting adverse outcomes included age >60 years and BNP level >29.2 pmol/l. Conclusion: Adverse factors affecting the long-term outcome of the disease (12±3 months after the STEMI) are: BNP level >29.2 pmol/l, CRP level >4.7 mg/l, LV FV value <42% and age >60 years.

Prerequisites and results of the work carried out by the Scientific Centre for Expert Evaluation of Medicinal Products on the standardization of the values of international non-proprietary, grouping and chemical names of drugs, anatomic-therapeutic-chemical classification, dosage forms, dosage units and other data are presented. The information is reduced to the same unique values in terms of information about identical drugs. This information is required for inclusion in a single directory drugs classifier, created to automate the management of drug purchases and implementation of a system for monitoring the movement of drugs. The work also substantiates the need for further revision and updating of the previously conducted work on the unification of information fields, and the revision of positions that did not previously require processing due to their uniqueness. The prospects for standardization of the description of medicines within the framework of the single market of the countries of the Eurasian Economic Union are outlined.

Thymus polypeptides participate in stress-limiting system work. Considering that electropain stimulation is the main stress factor in many behavioral models, it is logical to assume that thymus polypeptides have analgesic activity. The objective of this research is study of opioid and serotoninergic systems role of thymus polypeptides analgesic endpoints implementation. The rats presented with tactivin and thymulin thymus peptides analgesic activity during tail withdrawal test, which is totally blocked by naloxone, and thus is based on opioid system activation. This effect is associated with appeared serotoninergic component of stress-induced analgesia. The possible mechanism of analgesic action and the role of serotoninergic system of thymus peptides were offered based on the results of the research conducted.

According to current conception, the process of forming of nephrosclerosis despite the origins is detected by the force of the same cellular and molecular mechanisms. Hence primary triggers cause elevated production of range of cellular response mediators, cytokines and growth factors such as transforming plateled-derived growth factor, fibroblast growth factor, interferon gamma, nuclear factor and others, by means of sequential processes, is followed by the replacement of kidney tissue. One of the most studied aspects of the process of nephrosclerosis is the influence of anginotensin II. Therefore, despite the triggering factors, development and progression of nephrosclerosis all children with chronic renal disease are in a risk group with predisposition for renal insufficiency and it is required to prescribe nephroprotective therapy, i.e. the drugs that will influence one of the links of the nephrosclerosis, in order to slow down its progression. Currently, with nephroprotective goal in early age are used the following elements - angiotensin converting enzyme inhibitors and angiotensin receptors, antogonists (blockers). Lately, the active search for effective and safe drugs with nephroprotective effect on one side and great interest towards undiscovered before qualities of Vitamin D caused a huge amount of works that support the effect of Vitamin D. Prescription of Vitamin D to animals with uremia was followed by the drop of apoptosis of podocides and loss of the protein that is contained in the split diaphragm that caused decrease in proteinuria. Vitamin D suppresses protophibrotic TGF-B1 in tubular epithelial cells. The regression of tubulointerstitial phibrosis under the influence of Vitamin D was confirmed based on the cases of animals with obstruction of urethra. Along with the use of the mentioned above groups of drugs, which effectiveness was proved experimentally and clinically, we strongly believe the more thorough study of the Vitamin D drug use is needed, especially to study the prevention and slowing down of the progression of nephrosclerosis in the cases of children with chronic renal disease. It is crucial to detect the exact dosage of the drug, the prescription period and the methods for the control of the effective concentration of the drug.